The Ratio and Interaction Between Neurotrophin and Immune Signaling During Electroconvulsive Therapy in Late-life Depression

Overview

Journal Brain Behav Immun Health

Date 2021 Nov 29

PMID 34841285

Citations 2

Authors

Dore Loef

Kristof Vansteelandt

Mardien L Oudega

Philip van Eijndhoven

Angela Carlier

Eric van Exel

Didi Rhebergen

Pascal Sienaert

Mathieu Vandenbulcke

Filip Bouckaert

Annemiek Dols

Affiliations

Soon will be listed here.

Abstract

Background: Electroconvulsive therapy (ECT) is the most effective treatment for severe late-life depression (LLD), and several hypotheses on the precise working mechanism have been proposed. Preclinical evidence suggests that ECT induces changes in neurotrophin and inflammatory signaling and that these neurotrophic and inflammatory systems affect each other. We examine the relation, interaction, and ratio between the neurotrophic brain-derived neurotrophic factor (BDNF) and the proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α), and depression severity during ECT.

Methods: In this naturalistic longitudinal study, linear mixed models were used to analyze the relation between BDNF, IL-6, TNF-α, and depression severity (determined by the Montgomery-Åsberg Depression Rating Scale; MADRS) in 99 patients with severe LLD before ECT (T0), three weeks after the first ECT (T1), and one week after the last ECT (T2).

Results: No significant association was found between BDNF, IL-6 and TNF-α, and MADRS scores at any time point. However, a significant interaction between TNF-α and BDNF in relation to MADRS was established ( = .020) at all time points. With higher levels of TNF-α, the relation between BDNF and MADRS becomes more negative. Furthermore, a higher ratio of TNF-α/BDNF was associated with a higher score on the MADRS ( = .007).

Conclusion: A possible explanation for the absence of a significant coevolution between the proinflammatory cytokines and BDNF could be that the study design was unable to determine parameters shortly after ECT sessions. However, the TNF-α/BDNF ratio was positively associated with depression severity, and the association of BDNF-level and depression severity depended on the level of TNF-α. This suggests that the interaction and balance between neurotrophin and immune signaling, specifically BDNF and TNF-α, could be relevant in LLD. This could be a focus in future research regarding treatment and the working mechanism of ECT.

Citing Articles

Estrogen-immuno-neuromodulation disorders in menopausal depression.

Zhang Y, Tan X, Tang C J Neuroinflammation. 2024; 21(1):159.

PMID: 38898454 PMC: 11188190. DOI: 10.1186/s12974-024-03152-1.

Hippocampal neuroplasticity, major depression and, not to forget: ECT.

Sartorius A, Karl S, Zilles-Wegner D Mol Psychiatry. 2022; 29(1):1-2.

PMID: 36038727 PMC: 11078706. DOI: 10.1038/s41380-022-01746-w.

References

Gueorguieva R, Krystal J . Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry. 2004; 61(3):310-7. DOI: 10.1001/archpsyc.61.3.310. View

Bouckaert F, Dols A, Emsell L, De Winter F, Vansteelandt K, Claes L . Relationship Between Hippocampal Volume, Serum BDNF, and Depression Severity Following Electroconvulsive Therapy in Late-Life Depression. Neuropsychopharmacology. 2016; 41(11):2741-8. PMC: 5026743. DOI: 10.1038/npp.2016.86. View

Bouckaert F, Emsell L, Vansteelandt K, De Winter F, Van den Stock J, Obbels J . Electroconvulsive therapy response in late-life depression unaffected by age-related brain changes. J Affect Disord. 2019; 251:114-120. DOI: 10.1016/j.jad.2019.03.055. View

Balkowiec-Iskra E, Vermehren-Schmaedick A, Balkowiec A . Tumor necrosis factor-α increases brain-derived neurotrophic factor expression in trigeminal ganglion neurons in an activity-dependent manner. Neuroscience. 2011; 180:322-33. PMC: 3070813. DOI: 10.1016/j.neuroscience.2011.02.028. View

Patas K, Penninx B, Bus B, Vogelzangs N, Molendijk M, Elzinga B . Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features. Brain Behav Immun. 2013; 36:71-9. DOI: 10.1016/j.bbi.2013.10.007. View

Johnson V, Sharma R . Aluminum disrupts the pro-inflammatory cytokine/neurotrophin balance in primary brain rotation-mediated aggregate cultures: possible role in neurodegeneration. Neurotoxicology. 2003; 24(2):261-8. DOI: 10.1016/S0161-813X(02)00194-8. View

Guloksuz S, Rutten B, Arts B, van Os J, Kenis G . The immune system and electroconvulsive therapy for depression. J ECT. 2014; 30(2):132-7. DOI: 10.1097/YCT.0000000000000127. View

Brunoni A, Baeken C, Machado-Vieira R, Gattaz W, Vanderhasselt M . BDNF blood levels after electroconvulsive therapy in patients with mood disorders: a systematic review and meta-analysis. World J Biol Psychiatry. 2014; 15(5):411-8. DOI: 10.3109/15622975.2014.892633. View

Schulte-Herbruggen O, Nassenstein C, Lommatzsch M, Quarcoo D, Renz H, Braun A . Tumor necrosis factor-alpha and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J Neuroimmunol. 2005; 160(1-2):204-9. DOI: 10.1016/j.jneuroim.2004.10.026. View

10.

Yrondi A, Sporer M, Peran P, Schmitt L, Arbus C, Sauvaget A . Electroconvulsive therapy, depression, the immune system and inflammation: A systematic review. Brain Stimul. 2017; 11(1):29-51. DOI: 10.1016/j.brs.2017.10.013. View

11.

Rush G, ODonovan A, Nagle L, Conway C, McCrohan A, OFarrelly C . Alteration of immune markers in a group of melancholic depressed patients and their response to electroconvulsive therapy. J Affect Disord. 2016; 205:60-68. PMC: 5291160. DOI: 10.1016/j.jad.2016.06.035. View

12.

Giacobbo B, Doorduin J, Klein H, Dierckx R, Bromberg E, de Vries E . Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation. Mol Neurobiol. 2018; 56(5):3295-3312. PMC: 6476855. DOI: 10.1007/s12035-018-1283-6. View

13.

Jehn C, Becker B, Flath B, Nogai H, Vuong L, Schmid P . Neurocognitive function, brain-derived neurotrophic factor (BDNF) and IL-6 levels in cancer patients with depression. J Neuroimmunol. 2015; 287:88-92. DOI: 10.1016/j.jneuroim.2015.08.012. View

14.

Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P . The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging. 2004; 26(1):115-23. DOI: 10.1016/j.neurobiolaging.2004.03.002. View

15.

Bolwig T . How does electroconvulsive therapy work? Theories on its mechanism. Can J Psychiatry. 2011; 56(1):13-8. DOI: 10.1177/070674371105600104. View

16.

Sackeim H . The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001; 62 Suppl 16:10-7. View

17.

Rapinesi C, Kotzalidis G, Curto M, Serata D, Ferri V, Scatena P . Electroconvulsive therapy improves clinical manifestations of treatment-resistant depression without changing serum BDNF levels. Psychiatry Res. 2015; 227(2-3):171-8. DOI: 10.1016/j.psychres.2015.04.009. View

18.

Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1999; 59 Suppl 20:22-33;quiz 34-57. View

19.

Dols A, Bouckaert F, Sienaert P, Rhebergen D, Vansteelandt K, Ten Kate M . Early- and Late-Onset Depression in Late Life: A Prospective Study on Clinical and Structural Brain Characteristics and Response to Electroconvulsive Therapy. Am J Geriatr Psychiatry. 2016; 25(2):178-189. DOI: 10.1016/j.jagp.2016.09.005. View

20.

Bouckaert F, Sienaert P, Obbels J, Dols A, Vandenbulcke M, Stek M . ECT: its brain enabling effects: a review of electroconvulsive therapy-induced structural brain plasticity. J ECT. 2014; 30(2):143-51. DOI: 10.1097/YCT.0000000000000129. View